BioMérieux Advances Women's Health with New Diagnostic Submission

bioMérieux, a leader in in vitro diagnostics, has filed an application with the U.S. FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel. This automated PCR test aims to improve vaginitis diagnostics by providing quick results within 20 minutes at the point of care. Traditional diagnostic methods for vaginitis are often inaccurate, leaving many women undertreated. The new test seeks to improve accuracy and speed of diagnosis, aiding in more effective treatment.

The BIOFIRE® SPOTFIRE® VG Panel detects key causes of vaginitis, including bacterial, yeast, and parasite pathogens, providing comprehensive results with a single swab. Dr. Charles K. Cooper from bioMérieux highlights this innovation as a means to guide targeted treatment and alleviate symptoms, potentially reducing further health risks.

This submission marks bioMérieux's entry into women's health diagnostics, joining their existing portfolio for other infections. The company is also pursuing CE marking in the EU.